全文获取类型
收费全文 | 2762101篇 |
免费 | 205120篇 |
国内免费 | 4210篇 |
专业分类
耳鼻咽喉 | 38098篇 |
儿科学 | 90361篇 |
妇产科学 | 74117篇 |
基础医学 | 408869篇 |
口腔科学 | 77138篇 |
临床医学 | 249611篇 |
内科学 | 532037篇 |
皮肤病学 | 61831篇 |
神经病学 | 215182篇 |
特种医学 | 103774篇 |
外国民族医学 | 552篇 |
外科学 | 416401篇 |
综合类 | 57811篇 |
现状与发展 | 12篇 |
一般理论 | 964篇 |
预防医学 | 213885篇 |
眼科学 | 64987篇 |
药学 | 207537篇 |
11篇 | |
中国医学 | 6020篇 |
肿瘤学 | 152233篇 |
出版年
2019年 | 22735篇 |
2018年 | 31473篇 |
2017年 | 23766篇 |
2016年 | 26617篇 |
2015年 | 29970篇 |
2014年 | 42194篇 |
2013年 | 63367篇 |
2012年 | 86731篇 |
2011年 | 91865篇 |
2010年 | 54679篇 |
2009年 | 51675篇 |
2008年 | 86348篇 |
2007年 | 92035篇 |
2006年 | 93091篇 |
2005年 | 89769篇 |
2004年 | 86161篇 |
2003年 | 82521篇 |
2002年 | 80139篇 |
2001年 | 129222篇 |
2000年 | 132293篇 |
1999年 | 110481篇 |
1998年 | 30005篇 |
1997年 | 25887篇 |
1996年 | 26266篇 |
1995年 | 26549篇 |
1994年 | 24453篇 |
1993年 | 22997篇 |
1992年 | 85836篇 |
1991年 | 83894篇 |
1990年 | 81673篇 |
1989年 | 79067篇 |
1988年 | 72679篇 |
1987年 | 71206篇 |
1986年 | 66841篇 |
1985年 | 63773篇 |
1984年 | 47337篇 |
1983年 | 40174篇 |
1982年 | 23539篇 |
1979年 | 43479篇 |
1978年 | 30881篇 |
1977年 | 25734篇 |
1976年 | 24663篇 |
1975年 | 26560篇 |
1974年 | 31810篇 |
1973年 | 30387篇 |
1972年 | 28491篇 |
1971年 | 26905篇 |
1970年 | 25071篇 |
1969年 | 23699篇 |
1968年 | 21731篇 |
排序方式: 共有10000条查询结果,搜索用时 93 毫秒
51.
52.
53.
54.
55.
56.
Jesus K Yamamoto-Furusho Norma N Parra-Holgu n 《World journal of gastroenterology : WJG》2021,27(48):8242-8261
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years. 相似文献
57.
58.
W. Jeffrey Zabel Jessica L. Conway Adam Gladwish Julia Skliarenko Giulio Didiodato Leah Goorts-Matthews Adam Michalak Sarah Reistetter Jenna King Keith Nakonechny Kyle Malkoske Muoi N. Tran Nevin McVicar 《Practical radiation oncology》2021,11(1):e80-e89
PurposeAuto-contouring may reduce workload, interobserver variation, and time associated with manual contouring of organs at risk. Manual contouring remains the standard due in part to uncertainty around the time and workload savings after accounting for the review and editing of auto-contours. This preliminary study compares a standard manual contouring workflow with 2 auto-contouring workflows (atlas and deep learning) for contouring the bladder and rectum in patients with prostate cancer.Methods and MaterialsThree contouring workflows were defined based on the initial contour-generation method including manual (MAN), atlas-based auto-contour (ATLAS), and deep-learning auto-contour (DEEP). For each workflow, initial contour generation was retrospectively performed on 15 patients with prostate cancer. Then, radiation oncologists (ROs) edited each contour while blinded to the manner in which the initial contour was generated. Workflows were compared by time (both in initial contour generation and in RO editing), contour similarity, and dosimetric evaluation.ResultsMean durations for initial contour generation were 10.9 min, 1.4 min, and 1.2 min for MAN, DEEP, and ATLAS, respectively. Initial DEEP contours were more geometrically similar to initial MAN contours. Mean durations of the RO editing steps for MAN, DEEP, and ATLAS contours were 4.1 min, 4.7 min, and 10.2 min, respectively. The geometric extent of RO edits was consistently larger for ATLAS contours compared with MAN and DEEP. No differences in clinically relevant dose-volume metrics were observed between workflows.ConclusionAuto-contouring software affords time savings for initial contour generation; however, it is important to also quantify workload changes at the RO editing step. Using deep-learning auto-contouring for bladder and rectum contour generation reduced contouring time without negatively affecting RO editing times, contour geometry, or clinically relevant dose–volume metrics. This work contributes to growing evidence that deep-learning methods are a clinically viable solution for organ-at-risk contouring in radiation therapy. 相似文献
59.
60.
Rajiv V. Dave Baek Kim Alona Courtney Rachel OConnell Tim Rattay Vicky P. Taxiarchi Jamie J. Kirkham Elizabeth M. Camacho Patricia Fairbrother Nisha Sharma Christopher W. J. Cartlidge Kieran Horgan Stuart A. McIntosh Daniel R. Leff Raghavan Vidya Shelley Potter Chris Holcombe Ellen Copson Charlotte E. Coles Ramsey I. Cutress Ashu Gandhi Cliona C. Kirwan 《British journal of cancer》2021,124(11):1785
Background The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions.Methods This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting.Findings Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey.Conclusions The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown.Subject terms: Breast cancer, Surgical oncology, Health care economics, Quality of life, Health policy 相似文献